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Melanoma cells can adopt the phenotype of stromal fibroblasts by spontaneous cell fusion 
LV Kemény,1 Z Kurgyis,1 H Polyánka,1 T Dittmar,2 L Kemény1 and IB Németh1 1 University of 
Szeged, Szeged, Hungary and 2 University of Witten/Herdecke, Witten, Germany
After the removal of primary cutaneous melanoma some patients develop local recurrences, even 
after having histologically tumor-free re-excision. We hypothesized that recurrent tumor initiating 
cells could be present in the peritumoral stroma having fibroblast phenotype as a result of mela-
noma-fibroblast fusion. We established a cell fusion model in which human melanoma cell lines 
(A375, G671, SKMEL-2, SKMEL-5, UACC-257) stained with the intravital dye CellTracker Orange 
(CTO) were co-cultured for 24 hours with primary isolated human dermal fibroblasts (HDFs) stained 
with CellTracker Green (CTG). Cells positive for both dyes were considered spontaneously fused 
hybrid cells. All melanoma cell lines fused spontaneously with HDFs in vitro, detected by con-
focal microscopy and flow cytometry. Fluorescent in situ hybridization revealed that hybrid cells 
contained chromosomes from both parental cells. Hybrid cells were indistinguishable from HDFs 
based on their morphology and could lose the melanoma specific MelanA marker. To see whether 
melanoma-fibroblast fusion might be also relevant in vivo we used genomic BRAFV600E as a marker 
of melanoma cells in a patient diagnosed with BRAFV600E melanoma. Surprisingly, not only micro-
dissected melanoma cells, but also MelanA negative, smooth muscle actin positive peritumoral 
fibroblasts contained BRAFV600E mutation on a genomic level, most likely as a result of cell fusion. 
In conclusion, we showed that melanoma cells can fuse spontaneously with HDFs, and thereby 
tumor cells can acquire fibroblast morphology and lose melanoma specific marker MelanA, while 
still carrying the oncogene BRAFV600E mutation. Therefore, melanoma-fibroblast fusion might play 
a role in missing tumor cells by routine histological assessments and might explain an alternative 
mechanism of tumor dormancy as well.    
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Modelling melanoma metastasis using organotypic skin equivalent and zebrafish models 
D Hill,1 S Verykiou,1 N Robinson,2 B Chaudhry,1 S Przyborski2 and P Lovat1 1 Newcastle 
University, Newcastle Upon Tyne, United Kingdom and 2 Durham University, Durham, 
United Kingdom
Currently, mouse melanoma models are the ‘gold standard’ for all studies of melanoma, but are 
unable to model early stages of human melanoma and are limited by their expensive/time-consum-
ing nature. The aim of the present study was thus to develop improved models to monitor all stages 
of human melanoma growth, invasion and metastasis. We have created an in vitro full-thickness 
human melanoma skin equivalent (MSE) by seeding neonatal fibroblasts onto a polymer scaffolds 
(Alvetex) to create a dermal-like layer, which is then overlain with keratinocytes and melanoma 
cells. Immunofluorescence studies confirmed the presence of collagen I and III throughout the 
dermal-like layer, collagen IV at the dermal/epidermal junction, and cytokeratin I, XIV and invo-
lucin in the epidermal-like layers, indicating fibroblasts produce their own extracellular matrix 
supporting the formation of an intact epidermis. Melanoma cells expressing melan-A form nests at 
the dermal/epidermal junction, which expand over time and invade through the basement mem-
brane, demonstrating the ability of this MSE to investigate early stages of melanoma growth and 
invasion. To investigate migration/invasion in an in vivo microenvironment, as well as secondary 
tumour formation, we have also developed a zebrafish xenograft of human melanoma (ZMX) by 
microinjecting DiI-labelled melanoma cells into the yolk sac of 2 day old anaesthetised Flk1-GFP 
tagged ‘casper’ zebrafish embryos. Confocal fluorescence microscopy studies of the ZMX model 
in situ up to 5 days post fertilisation, revealed invasion of melanoma cells throughout the yolk 
sac and to the head and tail via the blood stream, indicating the ZMX model is applicable for the 
investigation of melanoma metastasis in vivo. Collectively, the combined use of these in vitro/in 
vivo models allows for the investigation of melanomagenesis, early invasion and metastasis in a 
representative microenvironment, which is an ideal approach through which to study deregulated 
cell signalling in melanoma and the validation of novel therapeutic strategies.    
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Dual role for ADAM-9 in melanoma development and metastasis in vivo. 
N Moro,2 A Schoenefuss,2 J Landsberg,1 T Tueting,1 C Mauch2 and P Zigrino2 1 Dermatology, 
University of Bonn, Bonn, Germany and 2 Dermatology, University of Cologne, Cologne, 
Germany
Several proteases have been implicated in the invasive process of cancer cells and these include also 
the ADAMs. The versatile functions of ADAMs and the documented evidence of their over-expres-
sion in a variety of tumors suggest that these proteins are potential targets for tumor therapy. In the 
past we have identified ADAM-9 as being induced in melanoma cells at the periphery of the tumor as 
well as in adjacent peritumoral stromal cells while ADAM-9 is detected at very low levels in normal 
skin. Therefore the aim of this work was to characterize the function of ADAM-9 in development 
and progression of melanoma in vivo using genetic mouse models We have crossed Adam-9-/- mice 
with Hgf/Cdk4 mutant mice known to spontaneously develop melanoma which histomorphology 
resemble human tumors. The generated animals, which are deficient for ADAM-9 in melanoma 
cells as well as in stromal cells, were treated with DMBA and tumor formation was followed over 
time. This analysis surprisingly revealed that in the absence of ADAM-9 initially a higher number of 
small tumors developed, whereas at later time points the number of the grown tumors was reduced 
compared to control animals. Analysis of proliferation, apoptosis and inflammation in the tumors 
and surrounding areas indicated that an altered proliferation of the tumor cells as well peritumoral 
macrophages infiltration contribute to the observed differences in tumor growth. Strikingly deletion 
of ADAM-9 resulted in a significantly reduced formation of lung metastases. Circulating melanoma 
cells were detected in the blood of tumor bearing animals, thus we hypothesize that reduced lung 
metastasis formation is likely due to altered extravasation. In support of this, in in vitro studies we 
could observe that ADAM-9 deficient melanoma cells displayed reduced adhesion to and transmi-
gration through an activated endothelial cell layer. Taken together, these data show that whereas 
expression of ADAM-9 initially negatively regulates tumor formation, later on in tumor development 
it functions as a pro-metastatic protein.    
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Melanoma aggressiveness correlates with low CD271 expression levels in 3-  dimensional 
tumor models 
A Saltari, F Truzzi, R Lotti, P Morandi, E Palazzo, A Marconi and C Pincelli University of 
Modena and Reggio Emilia, Modena, Italy
Melanoma is characterized by a poor prognosis, while few therapeutic options are available for the 
most advanced stages. Given that alterations in neurotrophin signal play a critical role in human 
cancers, we studied the activity of the neurotrophin receptor CD271 in the progression of mela-
noma. Cell lines derived from primary (WM115, SkMel28, WM793B) and metastatic melanomas 
(WM266-4 and 1205Lu) were grown by using 3dimentional (3D) models such as spheroids and 
skin equivalents. First, the validation of the 3D spheroids model through proliferation and invasion 
assays (collagen I invasion), showed a significant correlation between proliferation/invasion of 
spheroids and progression stage of the tumor cell lines. CD271 expression was high in poorly 
aggressive primary melanomas (98% in the least aggressive WM115 cell line) while it was sig-
nificantly less expressed in more aggressive cell lines, such as SkMel28 and 1205Lu (45% and 20 
%, respectevely), as shown by flow cytometry. Results were confirmed by Western blotting and 
confocal microscopy. Similarly, CD271 was found highly expressed in 3D skin equivalents derived 
from WM115 and tended to disappear in reconstructs from the most aggressive 1205Lu cell line. 
When spheroids were implanted into collagen I, CD271+ cells were confined to the body of the 
sphere, while CD271- were more invasive (p<0,01), as shown by immunohistochemistry. Moreover, 
CD271+ and CD271- melanoma cells were sorted from SKMel28. Spheroids obtained from CD271- 
cells showed higher proliferative and invasion abilities if compared to spheroids from CD271+ 
cells (p<0,01). Finally, siRNA-CD271 transfection in WM115 resulted in the acquisition of a more 
aggressive behavior with an increase in growth (p<0,01) and invasion ability (p<0,05). Conversely, 
CD271 overexpression in the most aggressive 1205Lu and SKMel28 spheroids resulted in a reduced 
proliferation. These results indicate that CD271 plays a crucial role in melanoma progression and 
could be used as a prognostic factor.    
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STINGing the tumor microenvironment for melanoma immunotherapy
O Demaria,1 D Speiser2 and M Gilliet1 1 Dermatology, CHUV, Lausanne, Switzerland and 2 
Ludwig Cancer Research Institute, Lausanne, Switzerland
Melanoma is a highly aggressive but potentially immunogenic cancer. Recent studies using anti-
CTLA4 and anti-PD1 antibodies for the treatment of metastatic melanoma have provided encourag-
ing evidence for the ability of the immune system to fight cancer. Much interest has been devoted to 
the tumor microenvironment as the site for suppression of spontaneous antitumor immunity. There 
is also evidence that this immunosuppressive environment can be antagonized by the induction of 
strong innate immune responses at the tumor site via activation of pattern recognition receptors. 
In 2013 a new viral induced innate immune activation pathway was discovered. It was known for 
many years that replicating DNA viruses in the cytosol of infected cells could induce potent type 
I IFN induction via the STimulator of INterferon Genes (STING) molecule. Years of research trying 
to identify the cytosolic DNA receptor have failed until the recent discovery that cytosolic ds viral 
DNA binds to the enzyme cyclic cGAMP synthase, which generates cyclic dinucleotide GMP-
AMP (cGAMP), that binds and activates STING to produce type I interferon. Here we investigate 
the role of this newly discovered innate immune pathway in promoting anti-melanoma immunity. 
In a mouse model of melanoma we show that intratumoral cGAMP injection stimulates STING 
signaling pathway and triggers potent systemic anti-tumor immunity that is effective in injected 
and distant untreated tumors. Intratumoral cGAMP was found to expand tumor-specific CD8 T 
cells and to drive their accumulation in injected and non-injected tumors. Depletion of CD8 T 
cells impedes cGAMP-induced anti-tumoral immunity. In addition, intratumoral cGAMP injec-
tion induces potent type I IFN expression at the injection site and blockade of type I IFN signal-
ing abolishes cGAMP-mediated anti-tumor immune response, indicating that the anti-melanoma 
immunity induced by cGAMP is type I IFN-dependent. Therefore, our work presents the efficacy 
of intratumoral injection of cGAMP and proposes the targeting of STING as a therapeutic strategy 
for advanced stage melanoma.    
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BRAF inhibitors reactivate tumor suppressive and oncogenic p53 activities in melanoma
E Botti,1 F Fausti,2 G Spallone,2 M Levesque,3 D Bergamaschi,4 L Guerrini,5 R Dummer3 and 
A Costanzo1 1 University of Rome “La Sapienza”, Rome, Italy, 2 University of Rome “Tor 
Vergata”, Rome, Italy, 3 University of Zurich, Zurich, Switzerland, 4 Blizard Institute, London, 
United Kingdom and 5 University of Milan, MilaN, Italy
Selective inhibition of mutated BRAF by RAF inhibitors in metastatic melanoma has resulted in 
better patient outcomes. Despite this, most patients develop resistance to BRAF inhibition due to 
the reactivation of MAPK and AKT pathways with increased proliferation and reduced sensitivity 
to apoptosis. Here we report that this secondary resistance to BRAF inhibition is coupled to p53 
activation. Melanoma cell lines showed different levels of resistance to Vemurafenib (PLX4032) but 
siRNA-mediated p53 K/O reduced PLX4032-sensitive cell lines growth and interestingly enhanced 
proliferation of PLX4032-resistant cells suggesting a reactivation of p53 growth suppressive func-
tions. In BRAFi resistant cells, ChIp experiments showed that p53 is directly recruited to promoter 
regions of HGF and KITLG to induce their transcription and conditioned medium from BRAFi 
resistant cells triggers invasiveness and resistance to BRAF inhibition in sensitive cells. Chronic 
PLX4032 treatment in resistant cells seems preferentially select the p53-72R. The P72R is a common 
polymorphism affecting p53 phosphorylation and the binding to p53 regulators resulting in alter-
ation of different biologic functions including apoptosis, DNA repair and cancer susceptibility. This 
p53-72R seems to promote an oncogenic transcriptional program by favouring a tumour promoting 
microenvironment through the induction of cytokines in a paracrine manner. This phenomenon is 
probably due to the ability of p53-72R to regulate transcription of KITLG through its preferential 
binding on G allele of a SNP (rs4590952) in a p53-binding site of KITLG, that was associated with 
large risk of cancer. P53 “oncogenic” reactivation can be converted into tumor suppression by 
treatment with Nutlin3 or p53 activator drug PRIMA-1.    
Pigmentation and Melanoma | ABSTRACTS
www.jidonline.org   S91
513
Large congenital melanocytic nevi harbor cells with clonogenic and tumorigenic properties
C Charbel,1 R Fontaine,1 N Kadlub,2 A Coulomb,2 A How-Kit,3 J Tost,3 A Picard,2 S Aractingi1 
and S Guégan1 1 INSERM UMR_S 938, Université Paris VI, Paris, France, 2 Assistance 
Publique - Hôpitaux de Paris, Paris, France and 3 Fondation Jean Dausset – CEPH, Paris, 
France
Large congenital melanocytic nevi (lCMN) are benign melanocytic proliferations that are present 
at birth and associated with an increased risk of melanoma transformation. Evidence suggests that 
they result predominantly from a post-zygotic somatic NRAS mutation. We addressed the question 
whether large CMN harbor cells displaying clonogenic and tumorigenic properties. Indeed, after 
having accumulated additional mutations, such cells could be implicated in melanoma transforma-
tion. Fifteen children with large CMN were included in the study. Analysis of stem cell/progenitors 
lineage markers and melanocytic lineage markers was performed using immunohistochemistry and 
flow cytometry. Subpopulations of lCMN cells expressed stem cell/progenitor lineage markers such 
as Sox10, Nestin, Oct4 and ABCB5. In vitro, 1 in 250 cells dissociated from fresh NRAS-mutated 
lCMN formed colonies that could be passaged. These colonies were enriched in NRAS-mutated 
cells. In vivo, lCMN specimens xenografted in immunocompromised mice expanded 4-fold. BrdU+ 
proliferating and label retaining melanocytes were found within the outgrowth cutaneous tissue of 
these xenografts which displayed the same benign nested architecture as the original nevus. On 
the other hand, lCMN cell suspensions were not able to expand when xenografted alone in Rag 
2-/- mice. Conversely, when mixed with keratinocytes, these cells reconstituted the architecture 
of the human nevus with its characteristic melanocyte layout, lentiginous hyperplasia and nested 
architecture. Overall, our data demonstrate that certain lCMN cell subtypes display stem cell fea-
tures such as clonogenic and tumorigenic potential and expand into nevus-like structures when 
cooperating with adjacent keratinocytes.    
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2-Deoxy-D-glucose can abolish the cisplatin-induced melanoma giant cell formation and 
enhance the cytotoxic effect of cisplatin on melanoma cells
C Wu,1 W Chuo,5 C Weng,2 S Chen3 and M Tai4 1 Department of Dermatology, Kaohsiung 
Veterans General Hospital, Kaohsiung, Taiwan, 2 Department of Biological Sciences, National 
Sun Yat-Sen University, Kaohsiung, Taiwan, 3 Center for Neuroscience, National Sun Yat-Sen 
University, Kaohsiung, Taiwan, 4 Center for Neuroscience, Institute of Biomedical Sciences, 
and Department of Biological Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan 
and 5 Department of Pharmacy, Tajen University, Pingtung, Taiwan
Melanoma is the most aggressive skin cancer and notoriously resistant to current chemotherapy. 
Cisplatin is one of the most potent anti-tumor agents. However, the chemoresistance of melanoma 
cells to cisplatin-based chemotherapy remains unclear. 2-Deoxy-D-glucose (2-DG) can enhance 
chemotherapeutic drug-induced damage in cancer cells while sparing the normal cells. In this study, 
we focused on the roles of cisplatin and 2-DG in chemoresistance of melanoma cells. We delin-
eated the morphological features of cisplatin-induced melanoma cells, investigated whether giant 
cells exhibit molecular markers and functions of cancer stem cells, and evaluated the therapeutic 
potential of 2-DG in chemoresistance of melanoma. We observed that cisplatin enhanced the for-
mation of giant cells in mouse and human melanoma cell lines. S100 overexpression and dramatic 
remodeling of actin network were found in giant cells compared with the control cells. In addition, 
the cisplatin-induced giant cells are more malignant due to the overexpression of chemoresistant 
gene ATP-binding cassette sub-family B member 5 (ABCB5) in these giant cells. The application 
of metabolic blocker, 2-DG, potently abolished the cisplatin-induced formation of giant cells and 
ABCB5 expression. Moreover, 2-DG can enhance the cytotoxic effect of cisplatin on melanoma 
cells. Our results prove that melanoma cells can transform into giant cells and are more resistant 
to cisplatin treatment, and such information are useful for the pathological examination of drug 
resistance and malignancy in melanoma. Finally, the targeting at the metabolic demand of giant 
cells may facilitate a novel anti-neoplastic strategy against melanoma.    
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Camellia Sinensis Leaf Extract inhibits melanin synthesis via ERK activation in Murine 
Melanocytes 
N Park, Y Na, H Lee and J Lee Skin Research Division, AmorePacific R&D center, Yongin-si, 
Republic of Korea
Camellia Sinensis Leafs has been demonstrated to potent anti-inflammatory, antioxidant, anti-mu-
tagenic and anti-carcinogenic activity. Among the bioactive compounds isolated from Camellia 
Sinensis Leafs, EGCG has various biological activities, including anti-oxidant and anti-aging activity. 
However, despite numerous reports, the inhibitory activity of Camellia Sinensis Leafs on the mela-
nogenesis signaling pathway is not completely understood. In this study, we examined the effects 
of Camellia Sinensis Leafs extracts (CSLE) on melanin biosynthesis and the cellular mechanisms 
involved in melanogenesis in melan a cells. We found that CSLE inhibited melanin production in 
a dose-dependent manner in melan a cells. And western blot analysis indicated that CSLE down-
regulated microphthalmia-associated transcription factor (MITF) and tyrosinase protein expression. 
Moreover, to elucidate the possible mechanism behind melanogenesis regulation, western blot using 
ERK pathway related antibody and PD98059 inhibitor analysis were carried out. Thus, these results 
suggest that CSLE induced melanin reduction is caused by ERK phosphorylation. In conclusion, this 
study demonstrated that CSLE is involved in the regulation of melanin synthesis through the down-
regulation of MITF and tyrosinase expression, which is caused by activation of the ERK pathway. 
CSLE has the advantages of already being approved for anti aging use. Thus, Camellia Sinensis Leafs 
extracts (CSLE) could feasibly be developed as a new skin lightening agent.    
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Caveolin regulates PTEN and b-catenin during melanomagenesis
L Larue and A Conde Institut Curie, Orsay, France
Loss of the tumor suppressor PTEN is often observed in human melanoma, after MAPK activa-
tion, and mediates metastatic behaviour. Here we show for the first time that knock-down or 
absence of PTEN in various epithelial and melanocytic cell lines induces the nuclear localization 
and transcriptional activation of β-catenin in a reversible manner. Surprisingly, this pathway is 
PI3K-AKT-GSK3-independent, as phosphorylation of β-catenin on Thr41 and Ser45 is not dramati-
cally affected by inhibition of these kinases, and rather depends on the endocytosis protein CAV1. 
PTEN and β-catenin compete for CAV1 and the relative amount of CAV1 affects the localization of 
β-catenin. The physiopathological importance of the lack of PTEN was evaluated using an NRAS 
relevant mouse melanoma model. In this model, PTEN loss bypassed senescence after inducing 
the nuclear localization of β-catenin and repression of p16INK4A, and induced efficient metastasis 
formation after E-cadherin internalization. Moreover, a feedback loop emerged between β-catenin 
and CAV1; β-catenin regulates the levels of miR199a-5p and miR-203, which are able to regulate 
the level of CAV1 mRNA in melanoma cells. Thus, our data reveal a novel mechanism, based on 
feedback regulation, by which loss of PTEN increases CAV1-mediated dissociation of membranous 
E-cadherin from β-catenin. In turn, the transcriptional activity of β-catenin is modulated by PTEN 
and/or CAV1.    
517
Changes in ROR α expression during progression of melanocytic tumors 
AA Brozyna,1 W Jozwicki,1 Y Takeda,2 AM Jetten2 and AT Slominski3 1 Department of Tumor 
Pathology and Pathomorphology, Oncology Center, Rydygier Collegium Medicum, NCU, 
Bydgoszcz, Poland, 2 Cell Biology Section, Division of Intramural Research, NIEHS, NIH, 
Research Triangle Park, NC and 3 Department of Pathology and Laboratory Medicine and 
Department of Medicine, University of Tennessee HSC, Memphis, TN
The retinoic acid-related orphan receptors (RORs) play a critical role in the regulation of a number of 
physiological processes, including of immune functions, metabolism, and cerebellar development. 
RORs control these processes through transcriptional regulation after binding to ROR-responsive 
elements in the regulatory regions of target genes. Recent studies have identified a number of 
ligands that interact with the ligand binding domain of RORs and that function as either as agonists 
or antagonists of RORs. Since there is a shortage of information on RORα expression in normal and 
pathological human skin, by means of immunohistochemistry we analyzed expression of RORα 
in tissue samples form 79 patients including 27 benign melanocytic nevi, 79 primary cutaneous 
melanomas, 39 metastases, and 11 normal skin biopsies. RORα was observed both in the cytoplasm 
and nucleus. The strongest cytoplasmic RORα level was observed in normal skin that gradually 
decreased with progression of melanocytic tumors. Concurrently nuclear RORα level was higher 
in tumors than in normal skin. Expression of both cytoplasmic and nuclear RORα was positively 
correlated with melanoma progression, and significantly lower RORα was observed in less advanced 
melanomas. There was also remarkable decrease of RORα level in nodular versus superficial spread-
ing melanomas. High RORα level correlated with brisk tumor-infiltrating lymphocyte response. In 
addition, RORα expression was inversely correlated to melanin content, the presence of ulceration 
and overall and disease-free survival. In conclusion, progression of melanocytic lesions and mela-
noma is associated with decreased RORα expression. Thus changes in RORα expression can serves 
as diagnostic and prognostic markers of melanoma development, and RORα may inhibit malignant 
transformation of melanocytes.    
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Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and 
autologous tumor cell-lines of stage III/IV melanoma 
A Knol,4 M Pandolfino,1 A Vallee,3 V Lella,5 G Quereux,2 S Saiagh,1 A Khammari,2 M Denis,3 
AJ Puaux5 and B Dreno2 1 UTCG, Institut de Biologie RJ-PT1, CHU Hotel Dieu, Nantes, 
France, 2 Unité de Cancéro-Dermatologie-CIC biothérapie INSERM 0503, CHU Hotel Dieu, 
Nantes, France, 3 Plateforme de Génétique des Cancers, CHU Hotel Dieu, Nantes, France, 4 
CRCNA, Inserm U892, CNRS6299, Laboratoire d’immuno-dermatologie, Institut de Biologie 
RJ-PT1, CHU Hotel Dieu, Nantes, France and 5 GlaxoSmithKline Biologicals SA, Rixensart, 
Belgium
In the last decade, advances in molecular biology have provided evidence of the genotypic 
hyper-variability of melanoma. The main objective of this work was to determine the presence 
of BRAF, NRAS and c-KIT alterations in a series of 63 FFPE tissue samples from stage III and IV 
melanoma patients and in the 63 autologous tumor cell-lines. Mutations were analyzed using either 
allele-specific PCR or quantitative PCR and sequencing in 63 FFPE samples of metastatic melanoma 
and in the 63 autologous tumor cell-lines. The expression of BRAF V600E protein was also inves-
tigated using an anti-BRAF antibody in the same FFPE tumor samples. 81% of FFPE samples and 
tumor cell-lines harbored a genetic alteration in either BRAF (54%) or NRAS (27%) oncogenes. The 
V600E mutation was the most commonly observed BRAF alteration, both in FFPE samples and tumor 
cell-lines. The p.Q61R mutation was the most frequently observed NRAS alteration, both in FFPE 
samples and tumor cell-lines. We observed a high concordance (98%) between tissue samples and 
tumor cell-lines in all but one discordant case. The BRAF V600E mutant-specific antibody showed 
high sensitivity (96%) and specificity (100%) for detecting the presence of a BRAF V600E mutation. 
The correlation was of 98% between PCR and immunohistochemistry results for BRAF mutation. 
These results suggest that the mutation status of tumor cells is not affected by culture conditions. 
Tumor cell-lines could thus be used to evaluate the sensitivity of a melanoma tumor to different 
pharmacologic agents targeting BRAF or NRAS mutations or a combined therapy. Funding source 
: GlaxoSmithKline Biologicals SA.    
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Comparative analysis of TRAIP expression in benign versus malignant melanocytic prolif-
erations: a pilot study 
E Chiticariu, D Hohl and M Huber Service of Dermatology, University Hospital Center of 
Lausanne, Lausanne, Switzerland
The TRAF-interacting protein (TRAIP) is a RING-type E3 ubiquitin ligase involved in the control 
of cell proliferation. TRAIP was reported to interact with the two tumor suppressor genes CYLD 
and Syk but its precise role in carcinogenesis remains unknown. Moreover, no data regarding the 
expression of TRAIP in melanocytic cells has been reported. Our aim was to assess the role of TRAIP 
in melanoma pathogenesis. TRAIP mRNA relative expression level was analysed in 10 melanoma 
cell lines and normal melanocytes from two different donors and 33 MLANA positive clinical 
samples (10 non-dysplastic nevi, 10 melanomas in situ, 13 malignant melanomas) by quantitative 
RT-PCR, using the delta-delta Ct method. TRAIP mRNA synthesis was suppressed in a melanoma 
cell line using lentiviral infection with two plasmids expressing shRNAs targeting TRAIP to examine 
whether TRAIP is required for melanoma proliferation. Mean difference between the groups was 
analysed using unpaired Student’s t-test. TRAIP was overexpressed in 5/10 melanoma cell lines by at 
least two-fold compared with normal melanocytes. The TRAIP and CYLD expression was inversely 
correlated in 6/10 melanoma cell lines. Median expression of TRAIP, normalised to an endogenous 
control gene (RPL13A), was 3 times higher in melanoma in situ (p=0.0263) and 5.9 times higher 
in malignant melanoma compared with benign nevi (p=0.0121). TRAIP positively correlated with 
MKi67 expression in cell lines and clinical samples. Suppression of TRAIP expression in a melanoma 
cell line with shRNAs giving a knock-down efficiency greater than 75% was leading to MKi67 
mRNA downregulation by more than 60% indicating that TRAIP is important for cell proliferation. 
We conclude that TRAIP is likely involved in proliferation control of the melanocytic cell lineages, 
with possible implications in melanoma progression and invasiveness.    
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Correlation among anti-tumor T cell response and the redox homeostasis in human cutaneous 
malignant melanoma
E Emri,1 EA Janka,1 G Boros,1 L Beke,2 C Hegedus,1 B Nagy,2 G Mehes,2 ÉVA Remenyik1 
and G Emri1 1 Department of Dermatology, Faculty of Medicine, University of Debrecen, 
Debrecen, Hungary and 2 Department of Pathology, Faculty of Medicine, University of 
Debrecen, Debrecen, Hungary
Prognosis of cutaneous malignant melanoma (CMM) depends on the characteristics of the tumor 
cells as well as on the host immune response. Molecular markers prescribing the relation between 
tumor cells and their microenvironment help to identify metastasis risk and to determine new 
therapeutic targets. Our findings suggest a link between redox processes in tumor cells and the host 
immune response. We compared CD8 and heme oxygenase-1 (HMOX1) protein expressions of 
primary melanoma samples without metastases (n=23) to samples with haematogenous metastases 
(n=23) in a retrospective manner using tissue microarray analysis of archived paraffin tissue blocks. 
Herein, statistically significant inverse correlation was demonstrated between CD68 (p=0,019) and 
CD163 (p=0,003) staining of tumor-infiltrating cells and HMOX1 staining of tumor cells. The cor-
relation between peritumoral CD1a+ cells and the HMOX1 expression of the tumor cells was linear 
(p=0,001). Metastatic tumors were characterized by low HMOX1 tumoral expression (p=0,003), but 
were associated with the presence of HMOX1+ cells infiltrating the tumor (p=0,039). These HMOX1 
expressing cells exhibited dendritic and spindle cell morphologies. Nevertheless, the presence of 
peritumoral CD8+ cells was more frequent in primary CMM without haematogenous metastasis 
(p=0,008). Peritumoral CD8 positivity were associated with the absence of CD68+ (p=0,048), 
CD163+ (p=0.003) cells infiltrating the tumor and with presence of CD1a+ (p=0,005) cells surround-
ing the tumor. Interestingly, significant correlation was found between CD8 peritumoral positivity 
and tumoral HMOX1 positivity (p=0,014) suggesting that production of reactive oxygen species 
and activation of the antioxidant pathway in melanoma cells might play a role in the modulation 
of the anti-tumor host immune response.    
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Delta-like protein 3 promotes proliferation and migration of melanoma cells
Y Kiniwa and R Okuyama Dermatology, Shinshu University School of Medicine, Matsumoto, 
Japan
Notch pathway is involved in differentiation of many kinds of tissues. It is also important for cancer 
progression in several kind of tumors. However, little is known about role of notch signaling in 
melanoma progression. In this study, we attempt to illustrate influence of Notch signaling, espe-
cially of Notch ligands in melanoma progression. We first tested mRNA expression of 5 ligands, 
including DLL1, DLL3, DLL4, JAG1 and JAG2 in melanoma. mRNA of DLL3 was preferentially 
expressed in melanoma rather than melanocytic nevus. To evaluate role of DLL3 in melanoma, 
we checked cell proliferation, cell migration, cell cycle and apoptosis using RNA interference and 
overexpression. Knocking down DLL3 inhibit cell proliferation of melanoma and induced G0/
G1 arrest in vitro. In addition, knocking down of DLL3 reduced both migration ability and colony 
formation ability of melanoma cells. There are no findings of apoptosis in DLL3-knocked down 
melanoma cells. Overexpression of DLL3 promoted migration ability of melanoma cells. Lastly, we 
found down-regulation of phosphor-ERK in DLL3-knocked down melanoma cell lines. Down-regu-
lation of phospho-ERK suggested that knocking down of DLL3 was involved in inhibition of MAPK 
signaling in melanoma. These results were compatible with induction of G1 arrest confirmed by 
flow cytometry. Consequently, our results suggested that DLL3 may be sufficient for progression 
and/or survive for melanoma cells.    
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Diclofenac sensitizes melanoma cells to TRAIL-induced apoptosis through upregulation of 
TRAIL-R2/DR5 in the resistant melanoma cells 
M Vazquez Strauss and G Stingl DIAID, Medical University of Vienna, Wien, Austria
Extensive research has led to demonstrate, in both humans and experimental animals, that induction 
of lytic molecules such as TNF-related Apoptosis Inducing Ligand (TRAIL) (e.g. by IFNα, Imiqui-
mod) endows immune cells with cytotoxic properties against cancer. To a varying extent, this is 
also true for melanoma. However, the wide spectrum of resistance/susceptibility to TRAIL-induced 
apoptosis found in diverse melanoma cell lines represents an important obstacle for the clinical 
application of TRAIL. To evaluate the mechanisms of TRAIL resistance we performed a qPCR array 
of 91 apoptosis-related genes and assessed the mRNA differential expression between two resistant 
(WM983A and 1205Lu) and one highly-susceptible (WM793) melanoma cell lines. We found the 
antiapoptotic molecule BCL2A1 to be constitutively expressed in higher levels in both resistant cell 
lines than in the susceptible cell line. We further observed that pretreatment with diclofenac of both 
WM983A and 1205Lu cell lines resulted in a higher susceptibility to TRAIL (diclofenac vs. control; 
WM983A: 71.70% vs. 27.00%; 1205Lu: 23.98% vs. 2.28% apoptotic cells, respectively). In fact, 
diclofenac treatment of WM983A cell line results in the upregulation of the death receptor TRAIL-R2/
DR5 as well as the proapoptotic molecules caspases 5 and 10, NOXA, CYCS, CHOP and XBP1, 
which may explain the sensitization of melanoma cell lines induced by diclofenac. Interestengly 
enough, we also found that stimulation of PBMCs with diclofenac as well as celecoxib results in 
the enhanced expression of TRAIL by different immune cell subpopulations (monocytes, mDC, 
pDC) in a magnitude similar to that observed with Imiquimod. These results suggest: that COX-2 
inhibitors would be a reasonable strategy to improve susceptibility of melanoma to the cytotoxic 
properties of the immune system, and that the antitumoral properties of COX-2 inhibitors are not 
only related to their direct effects on tumor cells but also to their capacity to promote a cytotoxic 
effector phenotype in immune cells.    
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Disruption of multiple signaling pathways in senile lentigo 
Y Zhuang, V Hariharan, J Lyga and U Santhanam Avon Products Inc., Suffern, NY
Senile lentigo (or age spots) are becoming a greater skin concern as the world’s population ages. 
Senile lentigos are hyperpigmented macules on the skin, having an irregular shape and they normally 
occur after the age of 40. Effective treatment for reducing the appearance of age spots is a major 
focus for dermatologists and researchers. However, the mechanism of how the age spots are formed 
is still not clear. In this study, we utilized a gene array approach to gain a more systematic view of 
changes in the area of age spots. 12 Caucasian women aged from 55-75 were recruited for the study. 
Biopsies were taken from lesional and peri-lesional areas of the skin, as well as sun-protected area. 
We identified differentially expressed genes by comparing gene expression profiles between lesional 
and peri-lesional area, as well as gene expression profiles between lesional and sun-protected area. 
Top differential signaling pathways identified include melanogenesis, cell invasion, cell migration 
and cell differentiation. This study provides a glimpse into how age spots may be formed and can 
help identify possible points of intervention.    
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Fibroblasts regulate both physiological and pathological pigmentation of skin in vitro and 
in vivo
M Cario-andre, A Taieb and K Ezzedine Inserm 1035, Bordeaux, France
We have previously described that white human skin xenografted onto nude mice could become 
black or totally white. These modifications of pigmentary pattern were associated with changes in 
densities of dermal fibroblasts. In vitro, we have compared reconstructs made on DDD colonized 
or not with various concentrations of normal fibroblasts and we have reproduced this phenomenon 
of increase or decrease of pigmentation. Furthermore since, in systemic scleroderma SSc, a disease 
characterized by an excessive secretion of collagen by fibroblasts, pigmentation changes are often 
marked, we have reconstructed epidermis on DDD colonized by fibroblasts of SSc patients and 
demonstrated that for a same seeding density, SSc fibroblasts can either stimulate or inhibit pigmen-
tation. Consequently, we looked at possible fibroblast-derived molecules and we focused on FGF-2 
which is a well-known pigment enhancer. The level of FGF2 was low in hypopigmented xenografts 
and high in hyperpigmented xenografts, showing an inverse correlation with the number of fibro-
blasts. In patients with SSc, FGF-2 was also differentially expressed. Using our model of reconstructs 
on DDD colonized by increasing densities of FGF2 overexpressing fibroblasts we observed that 
pigmentation and epidermal FGF-2 were not increased in presence of low or high number of FGF-2 
transduced fibroblasts. Since low level of FGF-2 was associated with depigmentation we measured 
it expression in skin biopsies of NSV patients: a significant decrease in FGF-2 in peri-lesional skin 
associated with an increased number of dermal vimentin positive cells. In vitiligo/NSV, the pattern 
of expression of FGF-2 is similar to that of one of its target molecule CCN3. Similar to NSV, CCN3 
expression in mouse xenografts and SSc patients followed that of FGF-2. In conclusion, our data 
associated with clinical observations in pigmentary disorders support the hypothesis that fibroblasts 
modulate pigmentation by paracrine factors especially the FGF2-CCN3 axis. CCN3 activity in skin 
should be investigated as possible target for the treatment of SSc patients with pigmentary troubles.   
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Gene Expression Profiling in Korean Women
B Chung,1 T Noh,1 S Yang,4 I Kim,3 M Lee,1 T Yoon2 and S Chang1 1 Department of 
Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic 
of Korea, 2 Institute of Health Sciences and School of Medicine, Gyeongsang National 
University, Jinju, Republic of Korea, 3 College of Medicine, Korea University, Seoul, Republic 
of Korea and 4 BK21 Yonsei Biomolecule Research Initiative, Yonsei University, Seoul, 
Republic of Korea
To date, there is a paucity of data about the difference in the degree of mRNA transcription of the 
genes between the malasma lesional skin and its normal adjacent one. We conducted this study to 
identify novel genes involved in the pathogenesis of melasma using gene expression profiling with 
microarray. In this study, we performed large-scale gene expression profiling using a microarray 
analysis and confirmed the results on the quantitative real-time polymerase chain reaction (qRT-
PCR) in five Korean women with melasma. There were 334 genes whose degree of expression 
showed a significant difference between the melasma lesional skin and its normal adjacent one. 
Of these, five genes were confirmed on both the microarray analysis and qRT-PCR. In the melasma 
lesional skin as compared with its normal adjacent one, there was down-regulation (> 2 fold) of 
genes involved in the PPAR signaling pathway (adiponectin, C1Q and collagen domain-containing 
(ADIPOQ)) and up-regulation of guanine deaminase (GDA) (9 fold), those involved in the functions 
of stratum corneum barrier (S100 calcium-binding protein A8 (S100A8), small proline-rich protein 
2A (SPRR2A), small proline-rich protein 2B (SPRR2B) and kallikrein-related peptidase 6 (KLK6)) (>2 
fold), NAD(P)H dehydrogenase, quinine 1 (NQO1) (>2 fold) and those involved in the tyrosine 
metabolism, the activity of testosterone 17-b-dehydrogenase or the arachidonic acid metabolism. In 
conclusion, our results indicate that the pathogenesis of melasma is associated with the up-regulation 
and down-regulation of novel genes involved in the PPAR signaling pathway, neuronal component 
and the functions of stratum corneum barrier in Korean women.    
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Genes and microRNAs regulating human skin pigmentation: Bioinformatics model and study 
on engineered pigmented epidermal epithelia. 
J Botto, C Serre, C Capallere, C Plaza, L Bergeron, V Busuttil and N Domloge Ashland 
Specialty Ingredients, Sophia Antipolis, France
Human skin pigmentation involves the two main cell types of the epidermis: melanocytes and 
keratinocytes. Melanocytes synthesize melanin with the help of melanogenic enzymes (tyrosinase...) 
and transfer it into basal keratinocytes, packed into melanosomes. Melanin is an excellent photo-
protectant able to absorb harmful solar UV irradiation and determines the phenotypic appearance 
of skin. Once in keratinocytes, melanosomes are organized as supranuclear caps, playing the highly 
essential role of protecting cell nuclei from UV radiation. As the keratinocyte undergoes terminal 
differentiation, melanosomes are degraded by controlled autophagy so that no melanosomes are 
visible in the very upper part of the epidermis. With the goal of studying the regulation of human 
skin pigmentation, we established a bioinformatics model taking into account several processes: 
melanocyte signaling pathways involved in the transcriptional regulation of melanogenic enzymes; 
tyrosinase and related enzymes; melanosomal packaging and transfer; autophagic melanin scav-
enging in keratinocytes; and inflammation. The major microRNAs described as potential controllers 
of human pigmentation were added to the model. In order to validate this model, we used 3D 
reconstructed epidermis containing both keratinocytes and melanocytes, and we applied classical 
compounds (e.g.kojic acid) known for their property to reduce skin melanin level. The expression 
level of specific genes and microRNAs was evaluated by RT-qPCR, following treatment.    
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Genomic expression differences between Red hair colour phenotype and Black hair colour 
individuals
J Puig-Butille,1 G Tell-Martí,2 A Visconti,3 M Escámez,4 F García,5 M Falchi,3 V Bataille,6 
J Dopazo,5 M del Río4 and S Puig2 1 Biochemistry and Molecular Genetics Department, 
Hospital Clinic & IDIBAPS (Institut d’Investigacions Biomèdiques Agustí Pi i Sunyer), 
Barcelona, Spain, 2 Melanoma Unit, Hospital Clinic & IDIBAPS (Institut d’Investigacions 
Biomèdiques Agustí Pi i Sunyer), Barcelona, Spain, 3 Department of Genomics of Common 
Disease, Imperial College London, London, United Kingdom, 4 Medicina Regenerativa. Div.
Biomedicina Epitelial, CIEMAT, Centro Investigación Biomédica en Red en Enfermedades 
Raras (CIBERER), Madrid, Spain, 5 Bioinformatics Department, Centro de Investigación 
Príncipe Felipe (CIPF), Centro Investigación Biomédica en Red en Enfermedades Raras 
(CIBERER), Valencia, Spain and 6 Department of Twin Research and Genetic Epidemiology, 
King’s College London, London, United Kingdom
The aim of the study was to identify differential expressed genes in skin from Red hair colour (RHC) 
individuals independently of the UV response. Expression data from cocultured keratinocytes and 
melanocytes from two RHC individuals and two Black hair (BHC) individuals was extracted using 
Whole Human Genome Microarray 4x44K (Agilent). Expression data from skin biopsies from 14 
RHC individuals and 7 BHC was extracted using Human HT-12 V3 BeadChips (Illumina). Differen-
tial gene expression data from co-cultures was evaluated by a protein–protein interaction network 
analyses to identify key deregulated genes in RHC individuals. The expression levels of those key 
genes were validated using the expression data from skin biopsies. Based on topological parameters 
of the networks, 24 genes involved in autophagy, oxidative phosphorylation and mithocondrial 
ribosome were classified as key genes. Differential expression of CLN3, SNX2, PCNA, ATG4C, 
ATG10, GBAS, RPA1, BRCA1, and WIPI2 genes were also observed in skin biopsies between RHC 
and BHC individuals. In conclusion, our results suggest that RHC indivuals have a constitutive 
deregulation of redox homeostasis processes and oxidative stress which can be involved in the 
increased skin cancer risk observed in these individuals.    
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GLI2 and ZEB1 are transcriptional regulators of the CDH2 gene expression in human mel-
anoma cells
C Perrot,1 C Gilbert,1 V Marsaud,1 P Marie,2 A Mauviel1 and D Javelaud1 1 Team “TGF-ß and 
Ocogenesis”, Institut Curie, Orsay, France and 2 U606, INSERM, Paris, France
This work was aimed at clarifying the molecular events that control the cadherin switch in mela-
noma. Our previous studies showed that GLI2 expression is associated with a loss of E-cadherin 
expression, and that GLI2 cooperates with ZEB1 to repress E-cadherin expression in melanoma 
cells. We herein demonstrate that N-cadherin expression is positively correlated to GLI2 and ZEB1 
expression in human melanoma cells and that GLI2 and ZEB1 control N-cadherin expression at 
the transcriptional level in melanoma cells via direct binding to the CDH2 promoter. Together, our 
results identify GLI2 and ZEB1 as master regulators of E- and N-cadherins, and thus play a pivotal 
role in the pseudo-EMT undergone by melanoma cells during the switch from radial to vertical 
growth phase of melanoma progression.    
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HIF-1α correlates inversely with VDR in cutaneous melanomas
AA Brozyna and W Jozwicki Department of Tumor Pathology and Pathomorphology, 
Oncology Center, Professor Franciszek Łukaszczyk Memorial Hospital, Ludwik Rydygier 
Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
Calcitriol, acting via vitamin D receptor (VDR), regulates wide spectrum of pleiotropic effects such as 
regulation of the immune and endocrine activities. It acts as a tumorostatic factor, protector against 
oxidative stress. It also regulates expression of adhesion molecules and inhibits angiogenesis. The 
hypoxia-inducible factor 1 alpha (Hif-1α) is a central mediator of cellular response to hypoxic con-
ditions. It promotes transcription of broad range of genes. HIF-1α is overexpressed in several types of 
human tumors, including melanoma and direct impacts several hallmarks of malignancy, including 
promotion of angiogenesis. Thus in the present study, we investigated the correlation between 
VDR and HIF-1α expression in cutaneous melanocytic lesions. Using immunohistochemistry, we 
analyzed expression of these proteins in 101 samples, including 26 benign melanocytic nevi and 
75 primary cutaneous melanomas, obtained from 84 patients. Nuclear HIF-1α was more frequent 
in malignant lesions and it was found in 60% of nevi and 77% of melanomas. VDR was localized 
in both the cytoplasm and nuclei of nevi and melanoma cells. In 67% and 84% of melanoma 
patients VDR was found in cytoplasm and nuclei, respectively. High VDR level was seen in the 
cytoplasm of only 12% of melanomas and in the cell nuclei of 17% of melanomas. Cytoplasmic 
and nuclear VDR was observed in all cases of nevi, and in 69% and 85% of nevi VDR level was 
high. In melanomas, the significant negative correlation between HIF-1α and cytoplasmic and 
nuclear VDR was observed. In benign lesions, the correlation between HIF-1α and VDR was not 
so distinct, and was observed only for cytoplasmic VDR. In conclusion, findings of this study and 
our previous research indicate that disturbances in VDR affect melanoma tumor behavior, allowing 
for progression of disease. Moreover, decreasing of VDR could promote melanoma malignant 
phenotype through HIF-1α-related pathways.    
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Immunotherapy with human iPS-cell derived myeloid cell lines producing Type I interferons 
against metastatic melanoma
A Miyashita,1 S Fukushima,1 S Nakahara,1 J Yamashita,1 D Niimori,1 S Senju,2 Y Nishimura,2 
M Jinnin1 and H Ihn1 1 Dermatology and Plastic Surgery, Kumamoto University, Kumamoto, 
Japan and 2 Immunogenetics, Kumamoto University, Kumamoto, Japan
In recent years, immunotherapy for malignant melanoma (MM) has been paid close attention by 
means of the efficacy of ipilimumab and Nivolumab have proved in clinical trials. As an immuno-
therapy, adoptive cell transfer has durable effects, however, it is difficult to have broad utility because 
the cell preparation for each patient is generally labor-intensive and expensive. To overcome these 
problems, we have conducted a study of immune cell therapy using iPS cells. The benefit of our 
method is that a large number of cells can be readily obtained, and it is able to express additional 
function on immune cells by genetic modification. We examined the efficacy of iPS-cell-derived 
myeloid cell lines (iPS-ML) as anti-cancer effector cells using genetically modification to express 
type I IFNs (iPS-ML-IFNα, iPS-ML-IFNβ) against disseminated MM in xenograft models. SCID mice 
were intraperitoneally injected with luciferase-expressing SK-MEL28 cells (10×106 cells/mouse). 
Tumor establishment and effect of treatment were evaluated using luminescence image analysis. 
Mice with established tumors were randomly divided into control and treatment groups. Mice in 
the treatment group were injected with iPS-ML, iPS-ML-IFN-α, iPS-ML-IFN-β (1×107 cells/mouse). 
Treatments with iPS-ML showed no inhibitory effect on the cancer cell growth, while iPS-ML-IFN-α, 
iPS-ML-IFN-β exhibited significant effects. Infiltration of iPS-ML into the tumor nests was observed 
immunohistologically. iPS-ML expressing type I IFNs increased expression of CD169, a marker of 
inflammatory macrophages, and produced IL-6, MCP-1, RANTES and IP-10 compared to iPS-ML 
without type I IFNs. In conclusion, this method will provide a new therapeutic modality for the 
peritoneally-disseminated patients with MM.    
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Inflammatory features of melasma lesions in Asian skin
T Noh,1 B Chung,1 J Kang,2 J Lee,3 M Lee1 and S Chang1 1 Asan Medical Center, University 
of Ulsan College of Medicine, Seoul, Republic of Korea, 2 Kangskin Clinic, Seoul, Republic 
of Korea and 3 Samsung Medical Center, Sungkwunkwan University School of Medicine, 
Seoul, Republic of Korea
Melasma is triggered by various factors including ultraviolet radiation and estrogen; however, its 
pathogenesis is unclear. To investigate the inflammatory features of melasma lesions as triggers for 
this disorder, 197 women with melasma who attended Asan Medical Center and Kang’s Dermatol-
ogy Clinic, Seoul, from June 2011 to October 2011 completed a questionnaire concerning triggering 
or aggravating factors. These cases were divided into ‘non-inflammatory’ and ‘inflammatory’ groups. 
Skin biopsies and immunostaining for CD68, CD117, and leukocyte common antigen (LCA) were 
performed in the lesional and peri-lesional skin of 10 cases in the non-inflammatory group and 
nine cases in the inflammatory group. Among the 197 subjects (mean age, 41.5 years; mean age of 
melasma onset, 33.8 years), 50 patients (25.4%) were categorized into the inflammatory group. This 
group comprised cases that had inflammatory symptoms and inflammatory events that triggered the 
melasma lesions. The lesional dermis contained more CD68+ melanophages, CD117+ mast cells, 
and LCA+ leukocytes in the inflammatory group than in the non-inflammatory group. Inflammatory 
clinical features and an increased number of inflammatory cells in the lesion may be involved in 
the development of melasma in Asian skin.    
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Inhibition of PKC reduces melanoma invasion
P Cheng,1 O Eichhoff,1 A Anastasov,1 A Weeraratna,2 R Dummer1 and M Levesque1 1 
Dermatology, University Hospital Zurich, Zurich, Switzerland and 2 The Wistar Institute, 
Philadelphia, PA
Melanoma is the most deadly skin cancer with rising incidence and few treatment options. It is a 
tumor with a high degree of heterogeneity and this phenotypic heterogeneity is dynamic. We and 
others have found that melanoma cells can express two distinct gene expression signatures and that 
these signatures correlate with in vitro characteristics like proliferation and invasion. In particular, 
Wnt5A is associated with tumor aggressiveness and directly correlates with increasing tumor stage. 
Overexpression of Wnt5A causes an epithelial to mesenchymal switch in a PKC dependent manner 
and subsequently, reduced expression of melanocyte antigens Melan-A, GP-100, and tyrosinase. 
We investigated the role of PKC signaling between the phenotypes and saw differential PKC iso-
form phosphorylation. High Wnt5A melanoma cells had PKC alpha phosphorylation whereas high 
Melan-A melanoma cells had PKC delta phosphorylation. We treated melanoma cell cultures of 
both phenotypes with AEB071, a specific PKC inhibitor, which resulted in decreased invasion 
by Boyden chamber assays and 3d spheroid assays but proliferation of both phenotypes were 
uninhibited. Using three-dimensional human skin reconstructs, treatment with AEB071 resulted 
in smaller tumor nodules and less infiltration into the dermis. In conclusion, our results suggest 
an important role for PKC signaling in melanoma invasion and inhibiting this pathway might be 
beneficial to delay metastasis.    
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Mast cell tryptase and chymase in cutaneous melanocytic lesions and lymph node metastases
H Siiskonen,1 K Tyynelä-Korhonen,2 R Sironen,3 SM Pasonen-Seppänen4 and I Harvima1 1 
Department of Dermatology, Kuopio University Hospital, Kuopio, Finland, 2 Cancer Center, 
Kuopio University Hospital, Kuopio, Finland, 3 Department of Clinical Pathology, Kuopio 
University Hospital, Kuopio, Finland and 4 Institute of Biomedicine, University of Eastern 
Finland, Kuopio, Finland
Melanoma is the most aggressive skin cancer with high morbidity, and mast cells are assumed to be 
involved in the pathogenesis. The aim of this study was to investigate the presence of tryptase+ and 
chymase+ mast cells in benign and malign cutaneous melanocytic lesions and lymph node metasta-
ses. Our material consisted of 28 benign (13 intradermal, 10 compound and 5 junctional nevi) and 
26 dysplastic nevi, 15 in situ melanomas, 36 superficially (pT1, Breslow < 1mm) and 45 deeply (pT4, 
Breslow > 4mm) invasive melanomas and 35 lymph node metastases. Paraffin-embedded sections 
were immunohistochemically stained for mast cell tryptase and chymase and immunopositive cells 
were counted with the hot spot –method. The mean count of tryptase+ mast cells was 31 in in situ 
melanomas, 26 in melanomas invading less than 1 mm, 19 in those invading more than 4 mm, 6 in 
lymph node metastases, 34 in intradermal, 22 in compound, 29 in junctional and 35 in dysplastic 
nevi. The mean count of chymase+ mast cells was 17 in in situ melanomas, 12 in melanomas 
invading less than 1 mm, 10 in those invading more than 4 mm, 4 in lymph node metastases, 17 in 
intradermal, 13 in compound, 18 in junctional and 18 in dysplastic nevi. In conclusion, our results 
show that the number of both tryptase+ and chymase+ mast cells is lower in melanomas compared 
to benign nevi. This may suggest a protective role for these enzymes. Although mostly found in the 
stroma, some mast cells also located in the tumor mass of invasive melanomas. Interestingly, some 
mast cells were present in lymph node metastases.    
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Melanoma–macrophage fusion can result in stealth tumor cells
Z Kurgyis,1 LV Kemény,1 H Polyánka,2 T Dittmar,3 L Kemény2 and I Németh1 1 Department 
of Dermatology and Allergology, University of Szeged, Szeged, Hungary, 2 Dermatological 
Research Group, Hungarian Academy of Sciences, Szeged, Hungary and 3 Institute of 
Immunology and Experimental Oncology, University of Witten/Herdecke, Witten, Germany
Macrophage infiltration in melanoma as well as CD68 expression in melanoma cells is associated 
with reduced survival. A potential explanation is that melanoma cells fuse with macrophages, 
gradually lose melanoma phenotype and acquire macrophage features but still have tumorous fea-
tures. Thus, they can be missed on routine histological examination but might contribute to tumor 
progression. We aimed to investigate whether such cells are present in human melanoma tissue 
samples and if they can result from cell fusion. To study spontaneous cell fusion in vitro, human mel-
anoma cell lines (A375, G361, SKMEL2, SKMEL5, UACC257) stained with the fluorescent vital dye 
CellTracker Orange were co-cultured for 24 hours with freshly isolated human monocytes stained 
with CellTracker Green. We detected the spontaneous formation of hybrid cells in all melanoma 
cell lines based on double positivity by fluorescent microscopy and flow cytometry. Fluorescent 
in situ hybridization confirmed that hybrid cells contained chromosomes from both parental cells. 
Hybrid cell morphology could resemble not only melanoma cells but also macrophages. Hybrid cells 
could also adopt the phenotype of macrophages: certain hybrids were negative for MelanA, on the 
other hand they could be positive for CD68. Such melanoma-macrophage hybrids could be iden-
tified ex vivo in BRAFV600E mutant human melanoma tissue samples as well, as certain peritumoral 
MelanA+CD68+ and MelanA-CD68+ macrophages, isolated with laser capture microdissection, 
contained BRAFV600E mutation on a genetic level. According to our results spontaneously fused 
melanoma-macrophage hybrids can have macrophage morphology and phenotype; therefore they 
can be missed on histological examinations. However, these stealth cells might contribute to the 
progression of melanoma as they carry tumorigenic genomic information.    
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miR-330-5p targets Tyrosinase and regulates pigmentation
F Rambow,1 A Bechadergue,1 G Saintigny,2 F Morizot,2 C Mahe2 and L Larue1 1 Institut Curie, 
Orsay, France and 2 Chanel Parfum Beauté, Pantin, France
Gene regulation is complex and highly regulated. Non-coding RNA including miRNA are key 
regulators of gene expression which are involved in various cellular mechanisms. Melanogenesis 
includes the synthesis of melanin and its distribution by melanosomes to surrounding keratinocytes. 
Recently, different miRNAs such as miR-145, miR-203, miR-125b, and miR-675-3p for humans, and 
miR-434-5p for mice have been shown to interfere with melanogenis. These observations identify 
miRNAs as promising targets to treat pigmentory disorders. However, different pigmentation genes 
are more suitable targets than others when thinking about a miRNA-based strategy. For example, the 
expression of MITF-M, which controls the expression of various genes involved in melanogenesis, is 
essential to melanocyte proliferation/survival and hence should be avoided as a miRNA target. Thus 
we decided to identify miRNAs that may act on pigmentation levels without affecting the survival/
proliferation of melanocytes. We applied an in silico sequence-based prediction approach which 
aimed to identify miRNAs targeting most likely TYR but not MITF. From this approach, miR-330-5p 
turned out to be the most attractive candidate. miR-330-5p is able to target TYR and act on melanin 
levels in various human melanoma cel llines and normal human epidermal melanocytes (NHEM). 
Moreover, miR-330-5p does not affect cell morphology, proliferation and survival. Mechanistically, 
miR-330-5p binds to the position 68-75 of the TYR 3’UTR, the WT and mutated predicted seed 
match region was cloned into a reporter vector, a significant reduction of Luciferase activity upon 
miR-330-5p overexpression in the WT situation was observed. Altogether, these results highlight 
the importance of miR-330-5p as a target to affect pigmentation.    
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NRAS π NRAS - Signaling of different NRAS mutations and potential clinical implications
C Posch,1 I Vujic,1 M Sanlorenzo,1 J Oses-Prieto,2 J Ma,1 ST Kim,1 K Lai,1 A Burlingame,2 
K Rappersberger3 and SM Ortiz-Urda1 1 Dermatology, University of California San 
Francisco, San Francisco, CA, 2 UCSF Mass Spectrometry Facility, San Francisco, CA and 3 
Dermatology, Krankenanstalt Rudolfstiftung, Vienna, Austria
Mutations in the NRAS oncogene are frequent in cutaneous melanoma and predominantly found 
in exon 2 and 3 impairing physiological cycling of the protein. Constantly active NRAS contributes 
to tumor growth, invasion and metastasis; still, it has yet been impossible to pharmaceutically 
target this protein. Even though mutations in exon 2 and 3 are both activating, each mutation 
has been recognized to affect protein function in a distinct ways; however, little is known about 
signaling differences resulting from these alterations. To investigate signaling of different NRAS 
mutations, we conducted a phosphoproteomic analysis of primary human melanocytes transduced 
with NRAS(G12), NRAS(Q61) or empty vector controls. Stable isotope labeling by amino acids in 
cell culture (SILAC) followed by MS-analysis identified 3371 unique phospho-peptides mapping to 
1159 different proteins. Phospho-proteins >2-fold differentially expressed between conditions were 
considered significant and their differential expression was validated by immunoblotting. Additional 
analysis included a motif search for detected phosphorylation sites and a kinase prediction analysis 
facilitating overrepresented motifs. Kinases most likely involved in phosphorylating the detected 
sites clustered for NRAS(G12) and NRAS(Q61). Kinases predicted to be differentially active between 
conditions were validated by immunoblotting, confirming the accuracy of the prediction model. 
Even though challenges remain confirming findings in melanoma cell lines, we found comparable 
differences in human NRAS mutant cell lines. Furthermore, expression of CK2α, a predicted over 
represented kinase in NRAS(Q61) cells, was present in NRAS mutant melanoma patient samples. 
Our findings highlight signaling changes of different NRAS mutants and might also provide a new, 
potentially interesting target for therapy of NRAS(Q61) mutant melanoma.    
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Podoplanin expression in cancer-associated fibroblasts predicts poor prognosis in melanoma 
but not in non-melanoma skin cancer 
J Asai,1 S Kan,1 E Konishi,2 T Arita,1 H Takenaka,1 A Yanagisawa2 and N Katoh1 1 
Dermatology, Kyoto Prefectural University of Medicine, Kyoto, Japan and 2 Surgical 
Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan
Recent studies have demonstrated podoplanin expression in several tumors, which has been asso-
ciated with lymph node metastasis and poor prognosis. Podoplanin expression in cancer-associated 
fibroblasts (CAFs) also correlates with tumor progression in several cancers. However, podoplanin 
expression and its association with skin cancer remain unclear. To clarify the prognostic significance 
of podoplanin in several skin cancers, podoplanin expression in tumor cells and CAFs was examined 
by immunohistochemistry in tissue samples from 55 melanoma, 9 merkel cell carcinoma, and 15 
extramammary Paget’s disease. In melanoma, podoplanin expression in tumor cells was identified 
in 38 patients (69.1%). Podoplanin expression in tumor cells was not correlated with characteristics 
of tumor progression such as tumor thickness and sentinel lymph node (SLN) metastasis. Podo-
planin expression in CAFs (CAF+) was observed in 25 patients (45.5%), including the 11 patients 
(44.0% in CAF+) with SLN metastasis. In contrast, only 4 of 30 patients with negative podoplanin 
expression in CAFs (13.3% CAF-) exhibited SLN metastasis. CAF+ was associated tumor thickness 
and SLN metastasis. Furthermore, patients with CAF+ had poorer disease-free survival than those 
with CAF- (P = 0.0148). On the contrary, podoplanin expression was not observed in tumor cells 
in Merkel cell carcinoma and extramammary Paget’s disease. In addition, podoplanin expression 
in CAF was rarely observed in these two carcinomas and not correlated with tumor progression. 
In conclusion, the presence of podoplanin expression in CAFs correlates with aggressive behavior 
in melanoma but not in other skin cancers, and may therefore serve as a useful prognostic factor 
for patients with melanoma.    
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Populus balsamifera extract: identification of two-distinct pathways for its anti-melanogen-
esis properties
P Portes,1 V Bardin,1 B Caprin,1 N Bechetoille,1 R Ballotti2 and F Demarne1 1 R&D, 
Gattefosse, Saint-Priest, France and 2 Biologie et pathologies des mélanocytes, Inserm 
U1065, Nice, France
Skin whitening is one of the most growing segments of the cosmetic industry, particularly with the 
increase of anti-aging products claiming an improvement of skin radiance for youthful-looking skin. 
While most of the main known whiteners act as direct tyrosinase inhibitors, we developed a safe 
plant extract of Populus balsamifera displaying inhibitor properties on other pathways involved 
in melanogenesis. To better understand the mechanism of activity, we assessed on aMSH-treated 
B16F10 cells (MSH-B16) several Populus balsamifera extracts derived from different extraction 
methods. Firstly, whatever the used extraction method, all extracts significantly decreased both 
melanin content and Tyrosinase and Silver protein expression in MSH-B16 as compared to untreated 
cells. Secondly, melanin-inhibiting properties were confirmed in normal human melanocytes but 
inhibition percentages were less effective than those in MSH-B16. Depending on the extraction 
method, two distinct plant extract groups were obtained, each exhibiting different anti-melanogenic 
effects. As compared to untreated/Group 1-treated MSH-B16, we showed Group 2-treated MSH-B16 
lost their dendritic morphology (for acquiring fusiform shape) and displayed large melanosomes, as 
evidenced by phalloidin and Tyrp1 staining, respectively. Moreover, Group 1 strongly decreased 
mRNA expression of several genes such as OCA2 in MSH-B16 while Group 2 had much less 
efficient effects. Taken together, we showed that whitening properties of our plant-based active are 
linked to inhibition of Tyrosinase and Silver protein expression. We hypothesize the two following 
mechanisms: 1/ loss of P protein (OCA2 gene) that could modify melanosome pH and conse-
quently, induce illegitimate degradation of both Tyrosinase and Silver by lysosomal proteases; 2/ 
morphology changes of cell and melanosomes. Fractioning the plant extracts in order to better 
know their composition will allow us to unravel all the efficient metabolic pathways inside the 
Populus balsamifera extract.    
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Prognostic significance of Nestin in primary malignant melanoma of the oral cavity 
S Kuk, H Yoon, S Hong, S Hong and J Lee Department of Oral Pathology, School of Dentistry 
and Dental Research Institute, Seoul National University, Seoul, Republic of Korea
There have been a number of reports on the correlation between Nestin and melanoma invasion 
in cutaneous melanoma. This study examined the prognostic significance of Nestin in primary 
mucosal melanoma of the oral cavity. Nestin and HMB-45 expression were examined immunohis-
tochemically in 39 cases. The following clinicopathological variables were evaluated: age, gender, 
tumor site, invasion depth, and disease progression-free survival (PFS). The associations of several 
parameters with PFS were evaluated using the Kaplan–Meier method and the multivariate Cox 
proportional hazards model. By Kaplan-Meier analysis, initial stage, invasion depth, the staining 
level of HMB-45, and the relative expression of Nestin compared to HMB-45 (but not the staining 
level of Nestin alone) were significantly associated with PFS. Three separate multivariate Cox 
proportional hazards models were performed for PFS combining these four variables. The level 
of HMB-45 was not significantly associated with progression, but the relative level of Nestin to 
HMB-45 was significantly associated with progression (high Nestin and high HMB-45 or low Nestin 
and low HMB-45: HR= 10.771, 14.097, and 8.412, P=0.039, 0.021 and 0.046; high Nestin and 
low HMB-45: HR= 59.597, 46.525 and 22.197, P=0.004, 0.010 and 0.009), as were initial stage 
(HR=17.254, P=0.008) and invasion depth (HR=4.753, P=0.035). These results suggest that tumor 
stage according to the 2010 American Joint Committee on Cancer system and invasion depth are 
effective predictors of oral malignant melanoma. Similar to initial stage and invasion depth, the ratio 
of Nestin expression relative to HMB-45 could be used to predict disease progression.    
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Senescence Induction in Metastatic Melanoma during Immunotherapy with Interferon–alpha
C Boss, E Brenner, H Braumüller, T Wieder and M Röcken Department of Dermatology, 
University of Tübingen, Tübingen, Germany
Induction of senescence is recognized as a barrier protecting against cancer development. While 
it was shown that melanoma immunotherapy can be therapeutically efficient, it remains enigmatic 
whether the therapeutic success depends only on mechanisms inducing cancer cell death, like cytol-
ysis or apoptosis, or whether it also involves growth inhibitory processes, e.g. senescence induction 
in the tumor cells. We have recently shown that proinflammatory cytokines are capable of stopping 
cancer growth through induction of senescence in a variety of malignant cells, including primary 
melanoma cells. To further analyze the effects of interferon (IFN) and tumor necrosis factor (TNF) 
on melanomas, we treated a panel of cell lines with these two cytokines. FACS analysis showed that 
the combined action of IFN and TNF can cause apoptosis and a senescence characterizing G0/G1 
arrest. Furthermore, we could detect an upregulation of senescence-associated-β-galactosidase and a 
stable cell cycle arrest in the cytokine-treated melanoma cells that remained stable after withdrawal 
of IFN and TNF. Moreover, the cytokine-treated melanoma cells showed a senescence-associated 
secretory phenotype with the production of IL-6, IL-8, IP-10 and CCL-2. In line with this, we could 
also detect IFN-alpha-induced senescence in primary cells from a patient with stage IV malignant 
melanoma in vitro, and, more importantly, during IFN-alpha immunotherapy of the same patient 
in vivo. The patient had an ECOG performance status of 4 due to a malignant ascites. The tumor 
board suggested a compassionate use treatment with IFN-alpha administered intraperitoneally. This 
treatment cleared the ascites completely, and the life quality was dramatically enhanced with an 
ECOG performance status of 1. Ex vivo analyses of the ascites-derived melanoma cells confirmed 
the induction of senescence during the treatment. Thus, interferon can drive human melanomas into 
senescence in vitro and in vivo, a discovery that is of great therapeutic relevance.    
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Serum levels of leptin receptor as a new tumor marker of malignant melanoma
S Fukushima, H Mizutani, A Miyashita, J Yamashita, S Nakahara, D Niimori, M Jinnin and 
H Ihn Dermatology and Plastic Surgery, Kumamoto University, Kumamoto, Japan
Leptin is known to be abnormally expressed in a variety of cancers, and leptin receptors have been 
reported to be expressed on human melanoma cells. In this study, we evaluated the possibility that 
the serum levels of leptin receptor could be a new tumor marker of malignant melanoma (MM). 
Serum samples were obtained from 71 patients with MM, and the serum levels of leptin receptor 
were measured by double-determinant ELISA. Interestingly, serum levels of leptin receptor decreased 
gradually with the stages of MM, being highest at in situ and lowest at stage IV. There was also a 
trend of reverse correlation between tumor thickness and serum levels of leptin receptor. There 
was a significant difference in the values between healthy controls and the patients with invasive 
MM of all subtypes. When the patients were classified into MM subtypes, serum levels of leptin 
receptor in patients with nodular melanoma and mucosal MM were significantly lower than those 
with acral lentiginous melanoma or those with lentigo maligna melanoma. When the patients with 
MM were divided into two groups according to the tumor thickness (<2 mm or >2 mm), there was 
significant difference in the serum levels of leptin receptor between the two groups (P = 0.0016). 
When the cut-off value was set at the mean – 2SD of the healthy controls, decreased serum levels 
of leptin receptor were found in 28 of the 71 MM patients (39.4%). The sensitivities of decreased 
serum leptin receptor levels in stage in situ, III and IV patients were 25.0%, 75.0% and 100%, 
respectively. The area under the curves was 0.714 (95% CI, 0.59 to 0.84). Serum samples were 
obtained from six MM patients who had experienced excisions of primary melanoma but who had 
developed a recurrence during the follow-up period. We found in 5 of the 6 patients that the serum 
levels were decreased at the point of recurrence. These results suggested that the serum levels of 
leptin receptor might serve as a useful biomarker for MM.    
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Skin microbiome in melanoma and melanocytic nevi 
A Salava,1 V Aho,2 P Pereira,2 K Koskinen,2 L Paulin,2 P Auvinen2 and A Lauerma1 1 
Department of Dermatology, Helsinki University Central Hospital, Helsinki, Finland and 
2 Institute of Biotechnology, DNA Sequencing and Genomics Laboratory, University of 
Helsinki, Helsinki, Finland
High-throughput DNA sequencing has revealed that the skin microbiome varies specifically due 
to different exogenous and endogenous factors. Interactions between the microbiome and the 
host immune system seem to play an important role in conducting the changes. Our object was to 
characterize the microbiome of cutaneous melanoma and melanocytic nevi. Non-invasive micro-
biome swab specimens were taken of 19 cutaneous melanomas, 15 dysplastic melanocytic nevi 
and 21 benign melanocytic nevi. Control samples were taken on the contralateral body side from 
the same patient’s healthy skin. Sequencing of the 16S ribosomal RNA gene, a common genetic 
marker for bacteria, was carried out on the 454 GS-FLX Titanium platform, and the abundances of 
bacterial genera in different samples were analyzed bioinformatically. Preliminary results show no 
differences in the relative abundances of bacterial genera or bacterial diversity between the patient 
groups, suggesting that the skin microbiome may not be a useful diagnostic tool for melanoma and 
melanocytic nevi. More data and larger cohorts of patients are needed to confirm these observa-
tions. It would be important to determine whether known melanoma risk factors like positive family 
history of melanoma, multiple melanocytic nevi and former dysplastic melanocytic nevi have an 
effect on the skin microbiome.    
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Solar lentigines on the shoulders and upper back in patients with cutaneous malignant mel-
anoma. Based on ultraviolet radiation photographs in an individually matched case-control 
study
L Winkel Idorn, P Alshede Philipsen and H Wulf Dermatological Research Department, 
Bispebjerg University Hospital, Copenhagen NV, Denmark
Previous studies suggest that solar lentigines of the skin are associated with risk of cutaneous malig-
nant melanoma (CMM). However, these studies have classified the number of solar lentigines into 
a maximum of 3 categories. The objective of the current observational case-control study was to 
investigate if the number of solar lentigines on the shoulders and upper back, counted in an indi-
vidual, is a risk factor for developing CMM. Forty-eight patients with CMM and 48 healthy controls 
completed the investigation. Controls matched CMM patients individually not only by age and 
gender, but also by constitutive skin type and occupation. Solar lentigines > 2 mm in diameter in an 
area of 95 cm2 on the shoulders and upper back were counted on ultraviolet radiation photographs 
to show additional sun damage. Patients with CMM had a higher number of solar lentigines on the 
shoulders and upper back compared with matched controls (P=0.04) using Wilcoxon matched-pairs 
signed rank sum test. Nonetheless, there was no association between the number of solar lentigines 
and CMM adjusted for age, sex and constitutive skin type in a multiple logistic regression analysis. 
Findings from the current study suggest that although patients with CMM have a higher number of 
solar lentigines on the shoulders and upper back compared with matched controls, the number of 
solar lentigines in an individual can not predict his risk of CMM.    
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Ultraviolet (UV)-A irradiation induces melanoma invasion via enhanced Warburg effect 
Y Kamenisch,2 TS Baban,1 W Schuller,1 T Sinnberg,1 G Metzler,1 J Bauer,1 C Garbe,1 
B Schittek,1 M Röcken1 and M Berneburg2 1 Dermatology, Eberhard Karls UNiversity 
Tübingen, Tübingen, Germany and 2 Dermatology, UKR - Universitätsklinikum Regensburg, 
Regensburg, Germany
Melanoma is a malignant tumor with high mortality and increasing prevalence for which exposure to 
ultraviolet (UV) radiation is considered to be an important risk factor. Especially UVA (320-400nm) 
radiation induces the formation of reactive oxygen species (ROS) which oxidatively damage cellular 
molecules. It was recently shown that UVA radiation is capable to induce murine melanoma, but 
the role of UVA in the progression of melanoma is still not investigated. During early progression 
of melanomas before metastasising, most melanomas show initial proliferation of melanoma cells 
and a metabolic characteristic of most proliferating tumor cells is the preference of aerobic glycol-
ysis instead of oxidative phosphorylation (Warburg effect). Here we investigated the role of UVA 
radiation in progression of melanoma, especially induction of progression markers, changes in 
Warburg effect and invasive potential. Upon UVA radiation, initial melanoma cells show increased 
Warburg effect with increased glucose consumption and increased lactate production. The tumor 
marker transketolase, involved in metabolic changes associated with proliferation, is also elevated 
upon UVA radiation. With in vitro invasion assays we show, that lactate, which is produced via 
UVA enhanced Warburg effect, increases invasiveness of initial melanoma cells. This effect is 
mediated by reactive oxygen species which are induced by UVA radiation as treatment with ROS 
scavengers impairs UVA induced lactate production and invasion. Furthermore transcription of 
tumor relevant matrix metalloproteinases and not TIMP1 is highly upregulated upon treatment with 
lactate. Therefore we could show in melanoma cells, derived from melanomas of early progression 
that production of lactate, induced by UVA radiation, increases invasiveness of initial melanoma 
cells via expression of MMPs.    
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Vitiligo: a disease of defect in energetic metabolism? 
M Dell’Anna,2 D Kovacs,1 G Cardinali,1 E Bastonini1 and M Picardo1 1 San Gallicano 
Dermatologic Institute, Rome, Italy and 2 San Gallicano Dermatologic Institute, Rome, Italy
The underlying pathogenic process of vitiligo is still debated. Previously, we showed that vitiligo 
melanocytes may be affected by a mitochondria-driven degenerative process leading to a pre-senes-
cent phenotype and affecting the capability to cope with stressful stimuli. We now also detected (n=6 
vs 6 healthy ones) an analogue phenotype with over expression of p53, GADD45 and IGFBP3 in 
vitiligo fibroblasts. Mitochondria may be the source of the uncontrolled ROS production giving rise 
to intracellular proteins modifications generating or unmasking antigenic epitopes and consequently 
an autoimmune response. Now, in vitiligo melanocytes (n= 18 vs 12 healthy ones) we search for 
index of mitochondrial impairment by cytomic approach and then we point on possible tracking 
features of the energetic metabolism including dissecting some steps of the intracellular signalling 
pathways. Cytomic analysis, revealed that the forward/side scatter ratio is significantly lower in 
vitiligo melanocytes than in normal ones (-40%) suggesting an increased mitochondrial mass. The 
metabolic impairment was characterized by an increased CxI expression (+20-40%), lower ATP 
production (-40%) and lower expression of some key glycolitic enzymes such as hexochinase II, 
piruvic dehydrogenase kinase 1 and piruvic kinase M2 respectively of 50% 20% and 30%. There-
fore it seems that cells can produce sufficient energy in steady-state conditions but are unable to 
cover further needs. The number of melanocytes bearing JNK phosphorylated, which probably 
targeted to mitochondria, was higher (+50%) in vitiligo. Probably to counteract the energy defect, 
an increased degree of CREB (+30%) and FAKy397 (+15%) phosphorylation and of the expression 
of the mitochondrial regulator FAK-dependent, PGC1a (+15%) which promote mitogenesis was 
detected. Ex vivo immuno histochemistry confirmed the increased mitochondrial mass and CxI 
expression in the entire epidermis. All these data indicated the existence of a metabolic inherited 
defect in vitiligo detectable in melanocytes and even in other skin cells.    
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Wedelolactone inhibits c-kit activation by SCF and reduces melanogenesis 
D Kim, Y Chang and S Lee LG Household&Health Care Research Park, Daejeon, Republic 
of Korea
In previous reports, it was shown that c-kit and SCF, a ligand of c-kit, are overexpressed in the 
lesion of melasma and that treatment of imatinib, inhibitor of c-kit, to cancer patients gives rise to 
hypopigmentation in the skin and hair. It means that c-kit inhibitor can be used as a new element 
to treat melasma and hyperpigmentation. To discover novel c-kit inhibitors, western blot analysis 
with phosphorylated c-kit antibody was performed using Mo7e cell treated with major compounds 
present in various natural herbs. Here we report that Wedelolactone, an active ingredient of Eclipta 
alba and Wedelia calendulacea, exhibits activity that inhibits phosphorylation of c-kit caused by 
SCF. As a result, Wedelolactone reduced melanogenesis in melanocyte, which was mediated by 
suppression of melanogenic enzyme expressions. Wedelolactone-induced phosphorylation of ERK 
and p38, leading to degradation of MITF, may be involved in inhibition of melanogenesis. Taken 
together, it suggests that Wedelolactone can be used as a new ingredient for cosmetics and drugs 
to treat the melasma through suppression of the c-kit activation by SCF and of melanogenesis.   
   
      
      
